Ngocdiep Le

Dr. NgocDiep (“Diep”) Le is the Global Chief Medical Officer (CMO) of Immorna. In this role, she is responsible for creating the company’s medical vision and leads the development and execution of the clinical development plan globally.

Dr. Le brings to Immorna over 20 years of drug development experience across early-to-late phases, with a track record of success in bringing innovative medicines to patients. Prior to joining Immorna, Dr. Le served as CMO at NeolmmuneTech where she successfully filed 10 Investigational New Drug applications, and at Verastem where she led the submission and achieved FDA approval for the company’s first product. Previously, she held leadership positions with increasing responsibilities at Medlmmune/AstraZeneca, Novartis, GSK and Amgen, most notable for her role in leading the GSK MEK inhibitor program from Phase 1 First-in-Human study to Phase 3 registrational studies and approval.

Dr. Le received her B.S. in Biology from the California Institute of Technology, earned her M.D. and Ph.D. degrees from Stanford University School of Medicine. She completed a Medical Oncology Fellowship at the Duke Comprehensive Cancer Center.